---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-048761"
form_type: "8-K"
ticker: "RCEL"
cik: "0001762303"
company_name: "AVITA Medical, Inc."
filed_at: "2026-02-12T23:59:59+00:00"
generated_at: "2026-05-16T03:05:26.725052+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# AVITA Medical Q4 revenue down 4% to $17.6M; FY2026 guidance $80-85M

## Summary
- Q4 revenue $17.6M (down 4% YoY); gross margin 81.2% vs 87.6%; net loss $11.6M ($0.38/sh) vs $11.6M ($0.44/sh).
- Full-year 2025 revenue $71.6M (+11% YoY); net loss $48.6M ($1.74/sh) vs $61.8M ($2.39/sh) in 2024.
- Net cash use improved to $5.1M in Q4; cash & marketable securities $18.2M at year-end.
- New $60M credit facility with Perceptive Advisors; initial $50M funded, used to repay existing debt.
- FY2026 revenue guidance $80-85M (12-19% growth); Cohealyx & PermeaDerm trials fully/significantly enrolled.

## SEC filing metadata
- accession: 0001193125-26-048761
- form_type: 8-K
- ticker: RCEL
- cik: 0001762303
- company_name: AVITA Medical, Inc.
- filed_at: 2026-02-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1762303/000119312526048761/0001193125-26-048761-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1762303/000119312526048761/rcel-20260212.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-048761
- JSON: https://secwatch.observer/filing/0001193125-26-048761.json
- Plain text: https://secwatch.observer/filing/0001193125-26-048761.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.